Adial Pharmaceuticals adjourns votes on Nasdaq-dependent proposals
The company adjourned votes on Proposals 3–6 at its 2026 annual meeting pending Nasdaq approval of its listing application. The meeting reconvenes Oct. 26.
The company adjourned votes on Proposals 3–6 at its 2026 annual meeting pending Nasdaq approval of its listing application. The meeting reconvenes Oct. 26.